MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xjon.2024.09.030

Медицинская библиотека · JTCVS open · 2024

Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma.

Dunne Elizabeth G, Fick Cameron N, Mastrogiacomo Brooke, Tan Kay See, Toumbacaris Nicolas, Vanstraelen Stijn, Rocco Gaetano, Chaft Jaime E, Iyengar Puneeth, Gomez Daniel, Adusumilli Prasad S, Park Bernard J, Isbell James M, Bott Matthew J, Sihag Smita, Molena Daniela, Huang James, Jones David R

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To identify clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma (LUAD) and to evaluate survival after brain metastasis.

METHODS

Patients who underwent complete resection of stage I-IIIA LUAD between 2011 and 2020 were included. A subset of patients had broad-based panel next-generation sequencing performed on their tumors. Fine-Gray models for the development of brain metastasis were constructed, with death without brain metastasis as a competing risk.

RESULTS

A total of 2660 patients were included. The median duration of follow-up was 71 months (95% confidence interval [CI], 69-73 months). The cumulative incidence of brain metastasis at 10 years was 9.8%. Among patients who developed a brain metastasis, the median time from surgery to brain metastasis was 21 months (interquartile range, 10-42 months). Higher maximum standardized uptake value of the primary tumor, neoadjuvant therapy, lymphovascular invasion, and stage III disease were associated with the development of brain metastasis. Among patients who underwent next-generation sequencing, a multivariable analysis identified neoadjuvant therapy, pathologic stage, and TP53 mutations as associated with development of brain metastasis. The median survival after brain metastasis was 18 months (95% CI, 13-24 months). Better performance status, lack of extracranial metastasis, stereotactic radiosurgery, and targeted therapy were associated with better survival after brain metastasis.

CONCLUSIONS

Brain metastasis is common after complete resection of LUAD and often occurs within 2 years. Markers of aggressive tumor biology, including higher maximum standardized uptake value, lymphovascular invasion, and TP53 mutations, and neoadjuvant therapy are associated with brain metastasis.

Для цитирования: Dunne Elizabeth G, Fick Cameron N, Mastrogiacomo Brooke, Tan Kay See, Toumbacaris Nicolas, Vanstraelen Stijn, Rocco Gaetano, Chaft Jaime E, Iyengar Puneeth, Gomez Daniel, Adusumilli Prasad S, Park Bernard J, Isbell James M, Bott Matthew J, Sihag Smita, Molena Daniela, Huang James, Jones David R. Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma.. JTCVS open. 2024. DOI: 10.1016/j.xjon.2024.09.030.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.